Selective COX-2 inhibitor-associated colitis: Two case reports;Colite aux anti-inflammatoires non stéroïdiens inhibiteurs préférentiels de la cyclo-oxygénase de type 2: A propos de 2 cas

Gastroenterologie Clinique et Biologique

Volumn 27, Issue 10, 2003, Pages 932-935

  D'Halluin, Pierre Nicolas ^a   Turlin, Bruno ^a   Polard, Elisabeth ^a   Dinasquet, Michel ^a   Pagenault, Maël ^a   Rioux, Nathalie ^a   Gosselin, Michel ^a   Bretagne, Jean François ^a   Heresbach, Denis ^a  

^a PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; COTRIMOXAZOLE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; MELOXICAM; NEXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; COLITIS; DISEASE COURSE; DRUG INDUCED DISEASE; ENDOSCOPY; FEMALE; HISTOLOGY; HUMAN; INTESTINE ULCER;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS; CYCLOOXYGENASE INHIBITORS; FEMALE; HUMANS; MIDDLE AGED; SULFONAMIDES; THIAZINES; THIAZOLES;

EID: 0242299084     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Siproudhis L, Beuchard J, Bretagne JF, Gosselin M. Entérocolites médicamenteuses (anti-inflammatoires non stéroidiens exclus). Gastroenterol Clin Biol 1995;19:B71-8.
2. Bjarnason I, Price AB. The small and large intestinal pathologies of non-steroidal anti-inflammatory drug ingestion. Ann Pathol 1994;14: 326-32.
3. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001;345:433-42.
4. Karmeli F, Cohen P, Rachmilewitz D. Cyclo-oxygenase-2 inhibitors ameliorate the severity of experimental colitis in rats. Eur J Gastroenterol Hepatol 2000;12:223-31.
5. Lesch CA, Kraus ER, Sanchez B, Gilbertsen R, Guglietta A. Lack of beneficial effect of COX-2 inhibitors in an experimental model of colitis. Methods Find Exp Clin Pharmacol 1999;21:99-104.
6. Reuter BK, Asfaha S, Buret A, Sharkey KA, Wallace JL. Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2. J Clin Invest 1996;98:2076-85.
7. Morteau O, Morham SG, Sellon R, Dieleman LA, Langenbach R, Smithies O, et al. Impaired mucosal defense to acute colonic injury in mice lacking cyclooxygenase-1 or cyclooxygenase-2. J Clin Invest 2000;105:469-78.
8. Hawkey C, Kahan A, Steinbruck K, Alegre C, Baumelou E, Begaud B, et al. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment. Br J Rheumatol 1998;37:937-45.
9. Dequeker J, Hawkey C, Kahan A, Steinbruck K, Alegre C, Baumelou E, et al. Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam compared with piroxicam: results of the Safety and Large-scale Evaluation of COX-inhibiting Therapies trial in osteoarthritis. Br J Rheumatol 1998;37: 946-51.
10. Wojtulewski JA, Schattenkirchner M, Barcelo P, Le L, X, Bevis PJ, Bluhmki E, et al. A six-month double-blind trial to compare the efficacy and safety of meloxicam 7.5 mg daily and naproxen 750 mg daily in patients with rheumatoid arthritis. Br J Rheumatol 1996;35 Suppl 1:22-8.
11. Distel M, Mueller C, Bluhmki E, Fries J. Safety of meloxicam: a global analysis of clinical trials. Br J Rheumatol 1996;35 Suppl 1:68-77.
12. Sigthorsson G, Simpson RJ, Walley M, Anthony A, Foster R, Hotz-Behoftsitz C, et al. COX-1 and 2, intestinal integrity, and pathogenesis of nonsteroidal anti-inflammatory drug enteropathy in mice. Gastroenterology 2002;122:1913-23.
13. O'Brien J. Nonsteroidal anti-inflammatory drugs in patients with inflammatory bowel disease. Am J Gastroenterol 2000;95:1859-61.
14. Kurahara K, Matsumoto T, Iida M, Honda K, Yao T, Fujishima M. Clinical and endoscopic features of nonsteroidal anti-inflammatory drug-induced colonic ulcerations. Am J Gastroenterol 2001;96:473-80.
15. Gibson GR, Whitacre EB, Ricotti CA. Colitis induced by nonsteroidal anti-inflammatory drugs. Report of four cases and review of the literature. Arch Intern Med 1992;152:625-32.
16. Davies NM. Toxicity of nonsteroidal anti-inflammatory drugs in the large intestine. Dis Colon Rectum 1995;38:1311-21.
17. Bridges AJ, Marshall JB, Diaz-Arias AA. Acute eosinophilic colitis and hypersensitivity reaction associated with naproxen therapy. Am J Med 1990;89:526-7.
18. Goldstein NS, Cinenza AN. The histopathology of nonsteroidal antiinflammatory drug-associated colitis. Am J Clin Pathol 1998;110: 622-8.
19. Baert F, Hart J, Blackstone MO. A case of diclofenac-induced colitis with focal granulomatous change. Am J Gastroenterol 1995;90:1871-3.
20. Puspok A, Kiener HP, Oberhuber G. Clinical, endoscopic, and histologic spectrum of nonsteroidal anti-inflammatory drug-induced lesions in the colon. Dis Colon Rectum 2000;43:685-91.
21. Verdier D, Mallet L, Terris G, Petite JP. Colite ischémique «spontanée»: colite infectieuse ou médicamenteuse? Presse Med 1992;21: 891-4.
22. Petit A, Guedon C, Duhamel C, Lerebours E, Colin R. Colites ischémiques «ambulatoires» aspects cliniques, évolutifs et étiologiques de 88 cas. Gastroenterol Clin Biol 1990;14:739-43.
23. Colin R, Hochain P, Czernichow, Petit A, Manchon ND, Berkelmans I. Non-steroidal anti-inflammatory drugs and segmental non-gangrenous colitis: a case-control study. Eur J Gastroenterol Hepatol 1993;5:715-9.
24. Gentric A, Pennec YL. Diclofenac-induced pseudomembranous colitis. Lancet 1992;340:126-7.
25. Giardiello FM, Hansen FC, III, Lazenby AJ, Hellman DB, Milligan FD, Bayless TM, et al. Collagenous colitis in setting of nonsteroidal antiinflammatory drugs and antibiotics. Dig Dis Sci 1990;35:257-60.
26. Ravi S, Keat AC, Keat EC. Colitis caused by non-steroidal anti-inflammatory drugs. Postgrad Med J 1986;62:773-6.
27. Carpenter HA, Talley NJ. The importance of clinicopathological correlation in the diagnosis of inflammatory conditions of the colon: histological patterns with clinical implications. Am J Gastroenterol 2000;95:878-96.
28. Lee FD. Drug-related pathological lesions of the intestinal tract. Histopathology 1994;25:303-8.
29. Garcia B, Ramaholimihaso F, Diebold MD, Cadiot G, Thiefin G. Ischaemic colitis in a patient taking meloxicam. Lancet 2001;357:690.
30. Patoia L, Santucci L, Furno P, Dionisi MS, Dell'Orso S, Romagnoli M, et al. A 4-week, double-blind, parallel-group study to compare the gastrointestinal effects of meloxicam 7.5 mg, meloxicam 15 mg, piroxicam 20 mg and placebo by means of faecal blood loss, endoscopy and symptom evaluation in healthy volunteers. Br J Rheumatol 1996;35 Suppl 1:61-7.
31. Felder JB, Korelitz BI, Rajapakse R, Schwarz S, Horatagis AP, Gleim G. Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a case-control study. Am J Gastroenterol 2000;95:1949-54.
32. Bonner GF, Walczak M, Kitchen L, Bayona M. Tolerance of nonsteroidal antiinflammatory drugs in patients with inflammatory bowel disease. Am J Gastroenterol 2000;95:1946-8.
33. Singer II, Kawka DW, Schloemann S, Tessner T, Riehl T, Stenson WF. Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel disease. Gastroenterology 1998;115:297-306.
34. Hendel J, Nielsen OH. Expression of cyclooxygenase-2 mRNA in active inflammatory bowel disease. Am J Gastroenterol 1997;92: 1170-3.
35. McCartney SA, Mitchell JA, Fairclough PD, Farthing MJ, Warner TD. Selective COX-2 inhibitors and human inflammatory bowel disease. Aliment Pharmacol Ther 1999;13:1115-7.
36. Bonner GF. Exacerbation of inflammatory bowel disease associated with use of celecoxib. Am J Gastroenterol 2001;96:1306-8.
37. Mahadevan U, Loftus EV, Jr., Tremaine WJ, Sandborn WJ. Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease. Am J Gastroenterol 2002;97:910-4.